Cookies on AgBiotechNet

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

News Article

Cellectis and Ozgene Enter License Agreement

Cellectis S.A., the genome engineering company, announced today that it entered into an agreement with Ozgene Pty Ltd. by which Cellectis granted Ozgene a worldwide non-exclusive commercial license under its patent family relating to a process for the specific replacement or insertion of a gene in an eukaryotic genome.

Cellectis S.A., the genome engineering company, announced today that it entered into an agreement with Ozgene Pty Ltd. by which Cellectis granted Ozgene a worldwide non-exclusive commercial license under its patent family relating to a process for the specific replacement or insertion of a gene in an eukaryotic genome. Under this agreement, Ozgene obtained a license from Cellectis for creating, developing and selling mice for use in the course of its activities relating to mouse knock-ins. Financial terms and conditions of the agreement were not disclosed. Isabelle Pelletier-Bressac, Cellectis’ Vice-President Business Development commented, "We are very pleased to have reached an agreement with Ozgene, one of the worldwide leaders in the production and sales of genetically modified mice for global biopharmaceutical market as tools in functional genomics and drug target validation". She added: "This agreement further supports Ozgene platform and should be beneficial for both companies". Eddie Noonan, Ozgene’ s Business Development Manager commented, "Ozgene is pleased to have entered into this agreement with Cellectis which further supports Ozgene services in the area of gene targeted mice".

Cellectis is applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-made Meganucleases for in vivo DNA interventions and also provides new tools for rational reverse genetics and targeted recombination. Cellectis develops Meganucleases that can induce unique site-directed double-strand breaks in a living cell, and can be used for biotechnological and therapeutical applications. The company is focusing on bringing "genome surgery" to clinic as a genuine new molecular medicine approach.

Ozgene Pty Ltd is a global provider of GM mouse and rat services, including vector design & construction, knockout & knockin mice, lentiviral tg mice & rats. These animals are tools in functional genomics and drug target validation. Ozgene’s customer base includes individual academics, research institutes and biotechnology/pharmaceutical companies from North & South America, Europe, Japan, China, Australia, and New Zealand.

Article details

  • Author(s)
  • David Hemming
  • Date
  • 12 July 2005
  • Subject(s)
  • Genetic engineering/ modification